Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

@article{Kantarjian2002HematologicAC,
  title={Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.},
  author={Hagop M Kantarjian and Charles L Sawyers and Andreas Hochhaus and François Guilhot and Charles A Schiffer and Carlo B. Gambacorti-Passerini and Dietger Niederwieser and Debra J Resta and Renaud Capdeville and Ulrike Zoellner and Moshe Talpaz and Brian J. Druker and JohnM. Goldman and Stephen G. O'Brien and Nigel H. Russell and Thomas Fischer and Oliver G Ottmann and Pascale Cony-Makhoul and Thierry Facon and Richard M Stone and Carole B. Miller and Martin S. Tallman and Randy Brown and Michael W. Schuster and Thomas Loughran and Alois A Gratwohl and Franco Mandelli and Giuseppe Saglio and Mario Lazzarino and Domenico Russo and Michele Baccarani and Enrica Morra},
  journal={The New England journal of medicine},
  year={2002},
  volume={346 9},
  pages={
          645-52
        }
}
BACKGROUND Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. METHODS A total of 532 patients with late--chronic-phase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses. Time to progression, survival, and toxic effects were… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 832 CITATIONS, ESTIMATED 52% COVERAGE

1,630 Citations

0100200'02'05'09'13'17
Citations per Year
Semantic Scholar estimates that this publication has 1,630 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…